The head of the industry-led Antimicrobial (AMR) Action Fund said the group is on track to begin investing in companies that manufacture promising new antibiotics by the first quarter of fiscal 2021, despite the COVID-19 pandemic. The organization, which comprises 23 major biopharmaceutical companies, expects to see more industry and non-industry investors join by the end of 2020. The AMR Action Fund, which launched in July with the goal of bringing two to four new antimicrobials to market by 2030...